The antiserum was produced against synthesized peptide derived from human AhR around the phosphorylation site of Ser36. AA range:2-51

Phospho-Ah Receptor (S36) Polyclonal Antibody detects endogenous levels of Ah Receptor protein only when phosphorylated at S36. .The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):NPsKR

AHR BHLHE76

Aryl hydrocarbon receptor

AHR ;
BHLHE76 ;
Aryl hydrocarbon receptor ;
Ah receptor ;
AhR ;
Class E basic helix-loop-helix protein 76 ;
bHLHe76 ;
AHRR ;
BHLHE77 ;
KIAA1234 ;
Aryl hydrocarbon receptor repressor ;
AhR repressor ;
AhRR ;
Class E basic helix-loop-helix protein 77 ;
bHL

The protein encoded by this gene is a ligand-activated helix-loop-helix transcription factor involved in the regulation of biological responses to planar aromatic hydrocarbons. This receptor has been shown to regulate xenobiotic-metabolizing enzymes such as cytochrome P450. Before ligand binding , the encoded protein is sequestered in the cytoplasm; upon ligand binding , this protein moves to the nucleus and stimulates transcription of target genes. [provided by RefSeq , Sep 2015] ,

Function:Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene) . Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and maturation of many tissues. ,induction:Induced or repressed by TGF-beta and dioxin in a cell-type specific fashion. Repressed by cAMP , retinoic acid , and TPA. ,similarity:Contains 1 basic helix-loop-helix (bHLH) domain. ,similarity:Contains 1 PAC (PAS-associated C-terminal) domain. ,similarity:Contains 2 PAS (PER-ARNT-SIM) domains. ,subcellular location:Initially cytoplasmic; upon binding with ligand and interaction with a HSP90 , it translocates to the nucleus. ,subunit:Binds MYBBP1A (By similarity) . Efficient DNA binding requires dimerization with another bHLH protein. In the nucleus , heterodimer of AHR and ARNT. Interacts with coactivators including SRC-1 , RIP140 and NOCA7 , and with the corepressor SMRT. Interacts with NEDD8 and IVNS1ABP. ,tissue specificity:Expressed in all tissues tested including blood , brain , heart , kidney , liver , lung , pancreas and skeletal muscle. ,

Cytoplasm . Nucleus . Initially cytoplasmic; upon binding with ligand and interaction with a HSP90 , it translocates to the nucleus. .

>>Th17 cell differentiation ;
>>Cushing syndrome ;
>>Chemical carcinogenesis - receptor activation ;
>>Chemical carcinogenesis - reactive oxygen species